Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 235 clinical trials
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Background Researchers are attempting to develop new treatments for hairy cell leukemia (HCL) that has not responded well to or has recurred after standard HCL therapies. One nonstandard treatment for HCL is rituximab, an antibody that binds to the cancer cells and helps the immune system destroy them. By combining …

  • 0 views
  • 18 Jun, 2022
  • 1 location
A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

This open-label, entry-into-human (EIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of RO7283420. Escalating doses of RO7283420 will be administered to participants with Acute Myeloid Leukemia (AML) in order to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D).

blast cells
graft versus host disease
tacrolimus
cyclosporine
  • 0 views
  • 15 Jun, 2022
  • 21 locations
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (Myechild01)

The main purpose of this study is : To establish which number of doses of gemtuzumab ozogamicin (up to a maximum of 3 doses) is tolerated and can be safety delivered in combination with cytarabine plus mitoxantrone or liposomal daunorubicin in induction To compare mitoxantrone (anthracenedione) & cytarabine with liposomal …

fludarabine
minimal residual disease
residual tumor
neoadjuvant therapy
cytarabine
  • 0 views
  • 26 Jan, 2022
  • 69 locations
MInimal Residual Disease Adapted Strategy (MIDAS)

IFM 2020-02 will enroll patients eligible for ASCT less than 66 years. All patients will receive induction based on 6 cycles (28-day) of KRD-Isatuximab (Isa-KRD), in order to achieve deep responses and high MRD negativity rates. Patients will be classified at diagnosis according to cytogenetics (standard vs high-risk cytogenetics defined …

  • 0 views
  • 26 Apr, 2022
  • 32 locations
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

ALLTogether collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several …

dexamethasone
inotuzumab
doxorubicin
vincristine
imatinib
  • 71 views
  • 15 Jun, 2022
  • 59 locations
ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT

A phase II trial of continuous intravenous infusion of Blincyto given over a 28-day cycle. Starting day for patients who are MRD-positive before HSCT is between day +60 and day +100 and for patients who become MRD-positive post HSCT it is between day +60 and day +360 post HSCT. Patients …

  • 0 views
  • 19 Mar, 2021
  • 14 locations
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

This phase III trial studies how well blinatumomab works in combination with chemotherapy in treating patients with newly diagnosed, standard risk B-lymphoblastic leukemia or B-lymphoblastic lymphoma with or without Down syndrome. Monoclonal antibodies, such as blinatumomab, may induce changes in the body's immune system and may interfere with the ability …

pegaspargase
thioguanine
lymphoblastic lymphoma
prednisone
leukemia
  • 92 views
  • 18 Jun, 2022
  • 111 locations
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, …

cytarabine/daunorubicin
mitoxantrone
cytarabine
cancer
methotrexate
  • 141 views
  • 10 May, 2022
  • 98 locations
A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML

Minimal-residual disease (MRD) will be measured either by flow cytometry, or polymerase chain reaction (PCR) methods, in 3 check-points and it will be one of the decision-making control

  • 17 views
  • 05 Feb, 2022
  • 1 location
De-escalated Treatment Approach for Adult Ph-negative Acute Lymphoblastic Leukemia (ALL)

markers, all included patients are monitored by flow cytometry by aberrant immunophenotype in a centralized lab.

ara-c
lymphoid leukemia
minimal residual disease
residual tumor
cytarabine
  • 30 views
  • 28 Feb, 2022
  • 1 location